Clinical trials for MALT lymphoma
39 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaGottfried von Keudell, MD PhD · PI: Gottfried von Keudell, MD, PhD
- RECRUITINGPhase 2NCT07441993Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLInstitute of Hematology & Blood Diseases Hospital, China · PI: Shuhua yi
- RECRUITINGPhase 2NCT07372365Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.The First Affiliated Hospital of Soochow University
- RECRUITINGNCT06712459Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone LymphomaInternational Extranodal Lymphoma Study Group (IELSG) · PI: Luca Arcaini, MD
- RECRUITINGPhase 2NCT06796998Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)Izidore Lossos, MD · PI: Izidore Lossos, MD
- ACTIVE NOT RECRUITINGPhase 2NCT07480863Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZLCancer Institute and Hospital, Chinese Academy of Medical Sciences · PI: Xinxin Cao, doctor
- ACTIVE NOT RECRUITINGPhase 2NCT07247383Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPhase 2NCT07208981Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPhase 2NCT06792825HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLMasonic Cancer Center, University of Minnesota
- RECRUITINGPhase 2NCT07448324Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPhase 2NCT06390956Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)University of Utah
- RECRUITINGPhase 2NCT06563505A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone LymphomaM.D. Anderson Cancer Center · PI: Dai Chihara, MD,PHD
- RECRUITINGPhase 2NCT06700798Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II TrialFei Li · PI: Fei Li, professor
- RECRUITINGPhase 2NCT06569680Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone LymphomaIzidore Lossos, MD · PI: Izidore Lossos, MD
- RECRUITINGPhase 2NCT06647732Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)Sun Yat-sen University
- ACTIVE NOT RECRUITINGPhase 2NCT06583837Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT LymphomaFudan University · PI: Rong Tao
- RECRUITINGPhase 2NCT06566807Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone LymphomaHuai'an First People's Hospital
- RECRUITINGPHASE1, PHASE2NCT06592170Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)The First Hospital of Jilin University
- RECRUITINGNCT06534463Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)Ruijin Hospital
- RECRUITINGPhase 2NCT06513234Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone LymphomasInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGN/ANCT06478472Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local TherapyThe First Affiliated Hospital of Xiamen University · PI: Bing Xu
- RECRUITINGPhase 2NCT06454968Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.Peking Union Medical College Hospital
- ACTIVE NOT RECRUITINGPhase 3NCT05735834Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL PatientsInternational Extranodal Lymphoma Study Group (IELSG) · PI: Davide Rossi, MD
- RECRUITINGPhase 2NCT06228963Orelabrutinib in the Treatment of HP-positive Gastric MALT LymphomaFudan University · PI: Yizhen Liu, M.D., Ph.D.
- RECRUITINGN/ANCT06190301RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT LymphomaZhongshan Ophthalmic Center, Sun Yat-sen University
- ACTIVE NOT RECRUITINGNCT06424379BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.Hospices Civils de Lyon
- RECRUITINGPhase 2NCT06503276The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and RadiotherapyShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · PI: Jun Shi
- RECRUITINGPhase 1NCT06026319CD79b-19 CAR T Cells in Non-Hodgkin LymphomaMarcela V. Maus, M.D.,Ph.D. · PI: Matthew Frigault, MD
- RECRUITINGPhase 3NCT06006117Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaThe Lymphoma Academic Research Organisation · PI: Catherine THIEBLEMONT, Pr
- RECRUITINGPhase 2NCT05929612A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone LymphomaM.D. Anderson Cancer Center · PI: Jillian Gunther, MD
- RECRUITINGPhase 4NCT06134284Clinical Study of OR for Second-line Treatment of Refractory MZLLixia Sheng · PI: Chen
- RECRUITINGPhase 3NCT04834024MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular LymphomaBeijing Mabworks Biotech Co., Ltd.
- ACTIVE NOT RECRUITINGPhase 2NCT04416451A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone LymphomaMemorial Sloan Kettering Cancer Center · PI: Andrew Zelenetz, MD, PhD
- ACTIVE NOT RECRUITINGPhase 3NCT04680052A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.Incyte Corporation
- ACTIVE NOT RECRUITINGPhase 2NCT03697512MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone LymphomasInternational Extranodal Lymphoma Study Group (IELSG) · PI: Catherine Thieblemont, MD
- ACTIVE NOT RECRUITINGEarly Phase 1NCT03680586Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT LymphomaM.D. Anderson Cancer Center · PI: Jillian Gunther
- ACTIVE NOT RECRUITINGPhase 2NCT03322865Obinutuzumab in Marginal Zone LymphomaChristian Buske · PI: Christian Buske, MD
- ACTIVE NOT RECRUITINGPhase 2NCT01808599Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT LymphomaInternational Extranodal Lymphoma Study Group (IELSG) · PI: Emanuele Zucca, MD
- ACTIVE NOT RECRUITINGPhase 2NCT01820910Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma TreatmentInternational Extranodal Lymphoma Study Group (IELSG) · PI: Andrés Ferreri, MD